Cargando…

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US

INTRODUCTION: The present study aimed to evaluate clinical outcomes and costs associated with timely versus delayed use of tumor necrosis factor inhibitors (TNFis) among patients with moderately to severely active psoriatic arthritis (PsA) with and without moderate/severe psoriasis (Ps) from a US pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Husni, Elaine, Griffith, Jenny, Zhou, Zheng-Yi, Signorovitch, James, Ganguli, Arijit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127966/ https://www.ncbi.nlm.nih.gov/pubmed/27747584 http://dx.doi.org/10.1007/s40744-016-0042-2

Ejemplares similares

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study
por: Husni, M. Elaine, et al.
Publicado: (2018)

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis
por: Song, Yan, et al.
Publicado: (2019)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis
por: Lucke, Michael, et al.
Publicado: (2016)

Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
por: Betts, Keith A., et al.
Publicado: (2016)

Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
por: Orbai, Ana-Maria, et al.
Publicado: (2021)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
por: Husni, M Elaine, et al.
Publicado: (2022)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2022)

Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
por: Strand, Vibeke, et al.
Publicado: (2012)

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis
por: Barbarroja, Nuria, et al.
Publicado: (2019)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
por: da Silva, Michael Ruberson Ribeiro, et al.
Publicado: (2022)

Delayed Diagnosis of Psoriatic Arthritis Mutilans due to Arthritis Prior to Skin Lesion
por: Mochizuki, Takeshi, et al.
Publicado: (2018)

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
por: Helliwell, Philip, et al.
Publicado: (2018)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
por: Coates, Laura C., et al.
Publicado: (2022)

Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
por: Ogdie, Alexis, et al.
Publicado: (2023)

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study
por: Aletaha, Daniel, et al.
Publicado: (2020)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
por: Strand, Vibeke, et al.
Publicado: (2018)

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study
por: Michielsens, Celia A J, et al.
Publicado: (2021)

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
por: Van Kuijk, Arno W R, et al.
Publicado: (2023)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis
por: Sauer, Brian C., et al.
Publicado: (2017)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5n7b1bnu4q9jiqsb46ukvqafnj